Jan Turek

Having run pharma and biotech companies at the most senior level, I take pride in delivering relevant, real-world solutions to our clients to build their company’s value.”

Primary Areas of Expertise

Focus: Pharma and Biotech Companies

Interim Leadership:

  • CEO of private Biotech companies
  • Portfolio strategy development and implementation
  • Geographic expansion plans and execution

Strategic Transactions:

  • In- and out-licensing / asset sales
  • M&A advisory services
  • Fundraising advisory services

Jan has 30 years of global experience in general management, product, business and market development as well as M&A/licensing with large and small pharmaceutical and biotechnology companies, working with small molecules, recombinant and plasma proteins.

Since joining TCG in 2012, Jan has led a number of strategic transaction projects for European and US companies, involving the development of new market entry strategies, licensing and acquisitions. His interim management assignments include acting as the Chief Commercial Officer for a publicly traded US pharmaceutical company and the CEO of a publicly traded Israeli biotech company.

Prior to joining TCG, Jan spent 11 years as CEO of Biolex Therapeutics, a venture-backed biotech company where he raised over $185 million to advance their pipeline of therapeutic proteins and antibodies in hepatitis C, cancer and vascular diseases. During his tenure, he successfully re-focused the company and led the negotiations of multiple technology and product licensing agreements with pharma/biotech companies.

Earlier, Jan spent 13 years at Bayer Pharmaceuticals, where he held senior country and international business positions in Canada, Germany and the US. Jan was Senior Vice President and General Manager of Bayer’s Biological Products Division, a $1 billion global business with recombinant and plasma proteins focused on coagulation, respirology and immunology. He managed over 3,000 people in research, development, production, finance, marketing and sales, and grew profits and sales through product line and geographic expansion strategies. His prior assignments at Bayer included head of world wide Cardiovascular (CV) and CNS Marketing where he led the re-positioning of the CV product line and re-focused the CNS pipeline to raise profitability. Jan joined Bayer in Canada as Marketing Director where he led the successful launches of the antibiotic, Cipro® (ciprofloxacin) and line extensions for the cardiovascular, Adalat® (nifedipene) in Canada. He began his career in Canada with Sandoz and then joined Bristol Myers (Mead Johnson Division) where he held marketing positions of increasing responsibility, implementing consumer-based marketing plans directed at physicians, patients and pharmacies.

Jan graduated from McGill University (BSc, Biochemistry) in Montreal, Canada. He is a past Board member of both the Southeast BIO and North Carolina BIO Associations.